Moderna Reports COVID-19 Vaccine Safe and Efficacious for Kids

Moderna’s COVID-19 vaccine is safe and efficacious for children ages 6 to 11 years old who recieve two half doses, the company said today. That’s based on the results of its KidCOVE study, which involved more than 4,700 kids in that age group. The children participating in Moderna’s trial were randomly assigned to receive two half doses of the vaccine or two shots of a placebo. Those who got the vaccine generated adequate virus-fighting antibodies that met the U.S. Food and Drug Administration’s (FDA) requirements for efficacy, and the vaccine produced an immune response in nearly all the children. Most of the side effects after vaccination were mild to moderate, including fatigue, fever, headache and pain at the injection site. Meanwhile, an independent FDA panel will review data on the Pfizer-BioNTech vaccine in children ages 5 to 11 on Oct. 26. The age range in KidCOVE varies slightly, given that Pfizer-BioNTech included children as young as 5. Moderna is continuing to study younger children and will report results on kids ages 2 to 5 and 6 months to under 2 years in the coming months. The FDA and Centers for Disease Control and Prevention recently authorized a half dose of Moderna’s vaccine as a booster for certain adults over 18 years old.
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news

Related Links:

DiscussionResults of this trial will help to clarify the value of auricular acupressure therapy in preventing and relieving overall and certain adverse events following immunization after injection of COVID-19 vaccine.Trial registrationChina Clinical Trial Registry (ChiCTR) (ChiCTR2100043210). Registered on 8 February, 2021.
Source: Trials - Category: Research Source Type: clinical trials
Lancet Infect Dis. 2021 Nov 23:S1473-3099(21)00677-0. doi: 10.1016/S1473-3099(21)00677-0. Online ahead of print.ABSTRACTBACKGROUND: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate.METHODS: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18-60 years and ≥61 years), adults with no history of virolo...
Source: Pain Physician - Category: Anesthesiology Authors: Source Type: research
Yonsei Med J. 2021 Dec;62(12):1162-1168. doi: 10.3349/ymj.2021.62.12.1162.ABSTRACTThe Pfizer-BioNTech COVID-19 vaccine has shown excellent clinical effectiveness; however, adverse events of the vaccine remain a concern in Korea. We surveyed adverse events in 2498 healthcare workers vaccinated with the Pfizer-BioNTech COVID-19 vaccine at a university hospital. The survey was conducted using a diary card for 7 days following each injection. The questionnaire response rate was 75.1% (1876/2498) for the first dose and 73.8% (1840/2493) for the second dose. Among local reactions, pain was the most commonly reported (84.9% after...
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Source Type: research
This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals vaccinated with ChAdOx1 nCoV-19 vaccine in Togo.MethodsA cross-sectional study was conducted from March 13th to 19th, 2021 in Togo among health professionals who received the first dose of the vaccine. An online self-administered questionnaire was used to collect sociodemographic and vaccination data. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Data analysis were performed using R ©...
Source: Archives of Public Health - Category: International Medicine & Public Health Source Type: research
CONCLUSION: BNT162b2 vaccination was tolerable among adults who were ≥ 75 years of age.PMID:34811980 | DOI:10.3346/jkms.2021.36.e318
Source: Journal of Korean Medical Science - Category: Biomedical Science Authors: Source Type: research
Discussion SARS-CoV-2 or COVID-19 was first observed in Wuhan China in late 2019. By March 2020 it had spread to become a world-wide pandemic and continues today despite vaccination and other public health measures. Early on people were worried that children would be the major age group affected, but the major groups were older individuals and those with underlying health problems. That is not to say that children are not affected as they were and could have severe disease. However as an overall group, they tend to get the virus and have less severe symptoms than adults. Severe disease is about 1% of pediatric cases compar...
Source: - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
We present two cases of ChAdOx1 nCov-19 (AstraZeneca)-associated thrombotic thrombocytopenia syndrome (TTS) and cerebral venous sinus thrombosis (CVST). At the time of emergency room presentation due to persistent headache, blood serum levels revealed reduced platelet counts. Yet, 1 or 4 days after the onset of the symptom, the first MR-angiography provided no evidence of CVST. Follow-up imaging, performed upon headache refractory to nonsteroidal pain medication verified CVST 2–10 days after initial negative MRI. Both the patients received combined treatment with intravenous immunoglobulins and parenteral anticoagula...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
CONCLUSIONS: The most common side effects of the Sputnik-V, AZD-1222, and Covaxin vaccine among Birjand (Iran) healthcare workers were injection site pain, muscle pain, fatigue, fever, and headache. Age and gender were the most important variables in the prevalence of vaccine side effects.PMID:34801416 | DOI:10.1016/j.intimp.2021.108351
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Source Type: research
Horm Mol Biol Clin Investig. 2021 Nov 17. doi: 10.1515/hmbci-2021-0037. Online ahead of print.ABSTRACTCOVID 19 is an infectious disease caused by severe acute respiratory syndrome corona virus 2. Thromboembolism has been a characteristic manifestation in most of the severely ill COVID-19 patients. Thromboembolism in COVID 19 infection is attributed to injury to the vascular endothelial cell, hypercoagulability and blood stasis. The hypercoagulable state of blood and thrombophilic diseases leads to hypercoagulability. COVID 19 infected patients with pre-existing hypercoagulable disorders have higher risk of developing throm...
Source: Mol Biol Cell - Category: Molecular Biology Authors: Source Type: research
The objective of this retrospective cross-sectional study was to generate real-world multiple sclerosis–specific vaccine safety information, particularly in the context of specific DMTs, and provide information to mitigate specific concerns in vaccine hesitant PwMS. Methods Between 3/2021 and 6/2021, participants in iConquerMS, an online people-powered research network, reported SARS-CoV-2 vaccines, experiences of local (itch, pain, redness, swelling, or warmth at injection site) and systemic (fever, chills, fatigue, headache, joint pain, malaise, muscle ache, nausea, allergic, and other) reactions within 24 hours (...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Public health, Multiple sclerosis, All epidemiology Article Source Type: research
More News: Centers for Disease Control and Prevention (CDC) | Children | COVID-19 | Food and Drug Administration (FDA) | Headache | Health | Migraine | Pain | Pfizer | Study | Vaccines